eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Upcoming Events
There are currently no events scheduled.